Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Victory Giant Technology -A / Equity Capital Markets

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, a number of companies are lininig up in Hong Kong to launch their IPOs soon.</li>
<li>On the placement front, there weren't many large deals given the ongoing market volatility.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, a number of companies are lininig up in Hong Kong to launch their IPOs soon.
On the placement front, there weren't many large deals given the ongoing market volatility.


Aequitas ECM Weekly (7 April 2026)-Victory Giant, Huaqin, Sigenergy, Manycore, WeWork, MTT, AVATR

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyse the changes of A-H premium on 181 stocks over the last week. The average A-H premium was 70.1% as of Apr 3rd.</li>
<li>The average A-H premium changed by 0.7ppt week-on-week, led by energy, financials, health care and offset by industrials, consumer discretionary.</li>
<li>We highlight weekly changes in A-H premium for Great Wall Motor, China Coal Energy, China Minsheng Banking, China Everbright Bank, CHALCO, Crrc.</li>
</ul>


We analyse the changes of A-H premium on 181 stocks over the last week. The average A-H premium was 70.1% as of Apr 3rd.
The average A-H premium changed by 0.7ppt week-on-week, led by energy, financials, health care and offset by industrials, consumer discretionary.
We highlight weekly changes in A-H premium for Great Wall Motor, China Coal Energy, China Minsheng Banking, China Everbright Bank, CHALCO, Crrc.


A-H Premium Weekly (Apr 3rd): Great Wall Motor, China Coal Energy, China Minsheng Banking

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Dizal Pharmaceutical / Equity Capital Markets

<ul>
<li>The flaws in DIZAL's pipeline stand out particularly prominent, as the success of a single product ZEGFROVY is not sufficient to sustain the long-term development of the Company.</li>
<li>Several senior executives, including Zhang Xiaolin, the Chairman of DIZAL, had intensively reduced their holdings in the company's shares in 2025, further raising market concerns about DIZAL's prospects.</li>
<li>Short-Term performance would still mainly rely on ZEGFROVY, as the sales of Golidocitinib is expected to be significantly lower than ZEGFROVY. Reasonable valuation of DIZAL should be lower than peers. </li>
</ul>


The flaws in DIZAL's pipeline stand out particularly prominent, as the success of a single product ZEGFROVY is not sufficient to sustain the long-term development of the Company.
Several senior executives, including Zhang Xiaolin, the Chairman of DIZAL, had intensively reduced their holdings in the company's shares in 2025, further raising market concerns about DIZAL's prospects.
Short-Term performance would still mainly rely on ZEGFROVY, as the sales of Golidocitinib is expected to be significantly lower than ZEGFROVY. Reasonable valuation of DIZAL should be lower than peers. 


Pre-IPO Dizal Pharmaceutical (A/H Listing)-Only Sunvozertinib Is Insufficient for Sustainable Growth

<ul>
<li>We analyse the changes of A-H premium on 181 stocks over the last week. The average A-H premium was 69.4% as of Mar 27th.</li>
<li>The average A-H premium changed by 0.4ppt week-on-week, led by industrials, utilities, energy and offset by real estate, communication services, information technology.</li>
<li>We highlight weekly changes in A-H premium for Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank, Cgn Power, ABC.</li>
</ul>


We analyse the changes of A-H premium on 181 stocks over the last week. The average A-H premium was 69.4% as of Mar 27th.
The average A-H premium changed by 0.4ppt week-on-week, led by industrials, utilities, energy and offset by real estate, communication services, information technology.
We highlight weekly changes in A-H premium for Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank, Cgn Power, ABC.


A-H Premium Weekly (Mar 27th): Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank, Cgn Power

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/shanghai-fosun-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:8045:1" rel="noopener">Shanghai Fosun Pharmaceutical (Group) (2196 HK) </a>reported revenue of RMB 41.5B, up 1%. Revenue from innovative drugs achieved robust growth of 30% as it garnered RMB 9.9B in sales.</li>
<li>In 2025, a total of 16 indications of 7 innovative drugs were approved for launch and the NDA for 6 Innovative Drugs have been accepted successfully.</li>
<li>The simultaneous increase in the proportions of innovative drugs revenue and overseas revenue reflects gradual emergence of innovation-driven development and internationalization. We remain bullish on the name.</li>
</ul>



Shanghai Fosun Pharmaceutical (Group) (2196 HK) reported revenue of RMB 41.5B, up 1%. Revenue from innovative drugs achieved robust growth of 30% as it garnered RMB 9.9B in sales.
In 2025, a total of 16 indications of 7 innovative drugs were approved for launch and the NDA for 6 Innovative Drugs have been accepted successfully.
The simultaneous increase in the proportions of innovative drugs revenue and overseas revenue reflects gradual emergence of innovation-driven development and internationalization. We remain bullish on the name.


Shanghai Fosun Pharma (2196 HK): Innovative Drugs Drive 2025, Internationalization Key For Future

China

Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.

Jiangsu Hengrui Pharmaceuticals (1276 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jiangsu Hengrui Pharmaceuticals (1276 HK)

Aequitas ECM Weekly (7 April 2026)-Victory Giant, Huaqin, Sigenergy, Manycore, WeWork, MTT, AVATR

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

A-H Premium Weekly (Apr 3rd): Great Wall Motor, China Coal Energy, China Minsheng Banking

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Great Wall Motor, China Coal Energy, China Minsheng Banking,...

Ke Yan, CFA, FRM

Pre-IPO Dizal Pharmaceutical (A/H Listing)-Only Sunvozertinib Is Insufficient for Sustainable Growth

DIZAL's pipeline flaws and heavy reliance on ZEGFROVY raise concerns about long-term sustainability and market prospects,with future performance...

Xinyao (Criss) Wang

A-H Premium Weekly (Mar 27th): Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank, Cgn Power

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank,...

Ke Yan, CFA, FRM

Shanghai Fosun Pharma (2196 HK): Innovative Drugs Drive 2025, Internationalization Key For Future

Shanghai Fosun Pharmaceutical Group reports 1% revenue growth, with innovative drugs sales up 30% to RMB 9.9B. Strong focus on innovation and...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aequitas ECM Weekly (7 April 2026)-Victory Giant, Huaqin, Sigenergy, Manycore, WeWork, MTT, AVATR

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

A-H Premium Weekly (Apr 3rd): Great Wall Motor, China Coal Energy, China Minsheng Banking

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Great Wall Motor, China Coal Energy, China Minsheng Banking,...

Ke Yan, CFA, FRM

Pre-IPO Dizal Pharmaceutical (A/H Listing)-Only Sunvozertinib Is Insufficient for Sustainable Growth

​DIZAL's pipeline flaws and heavy reliance on ZEGFROVY raise concerns about long-term sustainability and market prospects,with future performance...

Xinyao (Criss) Wang

A-H Premium Weekly (Mar 27th): Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank, Cgn Power

We analyzed A-H premium changes in the past week and highlight A-H premium changes for Hans Cnc, Air China, CATL, Chongqing Rural Commercial Bank,...

Ke Yan, CFA, FRM

Shanghai Fosun Pharma (2196 HK): Innovative Drugs Drive 2025, Internationalization Key For Future

​Shanghai Fosun Pharmaceutical Group reports 1% revenue growth, with innovative drugs sales up 30% to RMB 9.9B. Strong focus on innovation and...

Tina Banerjee

DIZAL's pipeline flaws and heavy reliance on ZEGFROVY raise concerns about long-term sustainability and market prospects,with future performance...

Shanghai Fosun Pharmaceutical Group reports 1% revenue growth, with innovative drugs sales up 30% to RMB 9.9B. Strong focus on innovation and...